What is the average price target for AGILON HEALTH INC (AGL) stock?
24 analysts have analysed AGL and the average price target is 21.99 USD. This implies a price increase of 15.63% is expected in the next year compared to the current price of 19.02.
AGILON HEALTH INC (AGL) Forecast, Price Target & Analyst Ratings
NYSE:AGL • US00857U1079
Current stock price
19.02 USD
-0.82 (-4.13%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AGILON HEALTH INC (AGL).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.32
- Revenue Estimate
- 1.406B
Price Target Details & History
Consensus Price Target and Range
Mean target
$21.99
Upside
+ 15.63%
From current price of $19.02 to mean target of $21.99, Based on 24 analyst forecasts
Low
$6.31
Median
$19.13
High
$52.50
Price Target Revisions
1 Month
2,087.31%
3 Months
2,134.46%
Price Target Summary
24 Wall Street analysts provided a forecast for the next 12 months for AGL. The average price target is 21.99 USD. This implies a price increase of 15.63% is expected in the next year compared to the current price of 19.02.
The average price target has been revised upward by 2134.46% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
55.00%
AGL was analyzed by 24 analysts. The buy percentage consensus is at 55. So analysts seem to be rather neutral about AGL.
In the previous month the buy percentage consensus was at a similar level.
AGL was analyzed by 24 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-02 | Benchmark | Maintains | Buy -> Buy |
| 2026-03-03 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-27 | Barclays | Maintains | Underweight -> Underweight |
| 2026-02-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-06 | Barclays | Maintains | Underweight -> Underweight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-20 | Bernstein | Downgrade | Outperform -> Market Perform |
| 2025-08-15 | Jefferies | Maintains | Hold -> Hold |
| 2025-08-14 | Baird | Maintains | Neutral -> Neutral |
| 2025-08-06 | Benchmark | Maintains | Buy -> Buy |
| 2025-08-06 | Barclays | Maintains | Underweight -> Underweight |
| 2025-08-06 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-07-09 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-05-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-08 | Barclays | Maintains | Underweight -> Underweight |
| 2025-05-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-04-28 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-04-25 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-04-15 | TD Cowen | Maintains | Hold -> Hold |
| 2025-04-15 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-08 | Bernstein | Upgrade | Market Perform -> Outperform |
| 2025-03-21 | Needham | Reiterate | Hold -> Hold |
| 2025-02-26 | Citizens Capital Markets | Reiterate | Market Perform -> Market Perform |
| 2025-02-26 | Needham | Reiterate | Hold -> Hold |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.32
- Revenue Estimate
- 1.406B
- Revenue Q2Q
- -8.27%
- EPS Q2Q
- 75.44%
- Number of Analysts
- 17
Next Earnings Revisions
Revenue (1 Month)
-1.26%
Revenue (3 Months)
-12.67%
EPS (1 Month)
2,027.98%
EPS (3 Months)
4,457.02%
Next Earnings Summary
AGL is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is 1.32 USD and the consensus revenue estimate is 1.41B USD.
The next earnings revenue estimate has been revised downward by 12.67% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2031
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.316B 59.38% | 6.061B 40.41% | 5.933B -2.11% | 5.513B -7.07% | 5.75B 4.30% | 6.568B 14.23% | 7.136B 8.65% | 7.814B 9.50% | 7.972B 2.02% | |
| EBITDA YoY % growth | -211.972M -98.79% | -264.071M -24.58% | -398.557M -50.93% | -30.545M 92.34% | -17.684M 42.11% | 67.829M 483.56% | 101.12M 49.08% | 136.66M 35.15% | 346.53M 153.57% | |
| EBIT YoY % growth | -232.133M -92.80% | -288.534M -24.30% | -427.151M -48.04% | -113.244M 73.49% | -100.558M 11.20% | -40.319M 59.90% | 104.94M 360.27% | 174.93M 66.70% | 250.48M 43.19% | |
| Operating Margin | -5.38% | -4.76% | -7.20% | -2.05% | -1.75% | -0.61% | 1.47% | 2.24% | 3.14% | |
| EPS YoY % growth | -12.25 -88.46% | -15.75 -28.57% | -23.75 -50.79% | -5.93 75.03% | -4.62 22.15% | -0.71 84.72% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.32 75.44% | -1.33 78.64% | -1.79 73.51% | -4.06 64.68% | 0.02 -98.43% | -0.03 97.71% | -0.03 98.18% | -0.14 96.66% |
| Revenue Q2Q % growth | 1.406B -8.27% | 1.372B -1.65% | 1.372B -4.41% | 1.402B -10.67% | 1.41B 0.28% | 1.418B 3.35% | 1.44B 4.96% | 1.5B 6.99% |
| EBITDA Q2Q % growth | 37.619M 346.94% | -2.787M 97.26% | -11.048M 89.92% | -55.191M 57.26% | 40.271M 7.05% | 11.66M 518.41% | 10.24M 192.69% | -43.159M 21.80% |
| EBIT Q2Q % growth | 10.183M 146.06% | -26.171M 77.44% | -31.545M 75.97% | -68.075M 56.84% | 5.909M -41.97% | -18.988M 27.45% | -16.059M 49.09% | -71.963M -5.71% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.37%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
3.75%
Revenue Next 5 Year
5.84%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
29.68%
EBIT Next 5 Year
18.78%
AGILON HEALTH INC / AGL Forecast FAQ
When does AGILON HEALTH INC (AGL) report earnings?
AGILON HEALTH INC (AGL) will report earnings on 2026-05-04.
What are the consensus estimates for AGILON HEALTH INC (AGL) next earnings?
The consensus EPS estimate for the next earnings of AGILON HEALTH INC (AGL) is 1.32 USD and the consensus revenue estimate is 1.41B USD.
What is the expected long term growth rate for AGILON HEALTH INC (AGL)?
The expected long term growth rate for AGILON HEALTH INC (AGL) is 3.75%.